







Our Pipeline

Meitheal is prioritizing a portfolio strategy centered on standards of care to ensure the ongoing availability of important biologics.

Brands										
Drug Name	Therapeutic Area	Type	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Submission	Approved	
XENLETA® (lefamulin)	Anti-Infective	Small Molecule								
Contepo™ (fosfomycin) for injection	Anti-Infective	Small Molecule								
XTMAB-16	Immunology & Inflammation	Biologic								

Biologics

Drug Name	Therapeutic Area	Type	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Submission	Approved	
BA1102 denosumab injection 120 mg through a partnership with Boan Biotech (reference product to Xgeva)	Oncology	Biosimilar								
YUSIMRY HC	Immunology & Inflammation	Biosimilar								
BA6101 denosumab injection 60 mg through a partnership with Boan Biotech (reference product to Prolia)	Oncology	Biosimilar								
Filgrastim	Oncology	Biosimilar								
Pegfilgrastim	Oncology	Biosimilar								
Follitropin alpha (FSH)	Fertility	Biosimilar								
Insulin Aspart	Diabetes	Biosimilar								
Insulin Glargine	Diabetes	Biosimilar								
Insulin Lispro	Diabetes	Biosimilar								